- Alliance will include Roivant's ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis
- Sumitomo Dainippon Pharma will leverage Roivant's technology platforms to digitally transform its business
- The new company will be led by Chief Executive Officer Myrtle Potter, former President and COO of Genentech and current Vant Operating Chair at Roivant
PR Newswire
TOKYO and OSAKA, Japan and LONDON and BASEL, Switzerland, Oct. 31, 2019